HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Pandemic Fraud Reports To FTC Spark Warnings Against IV Drip Services, Sonar Treatment Provider

Executive Summary

Complaints about potentially false COVID-19 claims are one source for FTC investigations to determine whether warnings or other enforcement are warranted. FTC's Consumer Sentinel Network includes nearly 10,000 pandemic fraud complaints, including reports of alleged losses from payments for goods and services not delivered or provided.

You may also be interested in...

US Enforcement On COVID-19 Consumer Health Fraud Circles Back To Ayurvedic Products

Georgia firm promoted a product as interrupting “infection chain” of coronavirus. Total of fraudulent COVID-19 claims FDA’s found in consumer health space approaches 200.

Like Health And Economic Impact, COVID-19 Unprecedented As Unlawful Claims Driver

Variety of products advertised with false coronavirus claims also grew in FTC's latest warnings submitted. It warned 21 firms on claims for products including IV drips, ozone therapy and stem cell treatments.

Federal Agencies Shut Down Church Group's Sales Of Bleach Mixture Promoted As COVID-19 Cure

The combination of Genesis II Church's rejection of FDA's warning, the potential for serious adverse events linked to its chlorine dioxide formulation and its claims the product treats COVID-19 led FDA to seek an injunction to stop sales of the product a week after it warned the group.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts